Tanvex BioPharma Inc Total Liabilities

Latest as of March 2026: NT$2.27 Billion TWD ≈ $71.64 Million USD

Tanvex BioPharma Inc total liabilities. Based on the latest financial reports, Tanvex BioPharma Inc (6541) has total liabilities worth NT$2.27 Billion TWD (≈ $71.64 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Tanvex BioPharma Inc to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Tanvex BioPharma Inc (2013–2025)

Total liabilities of Tanvex BioPharma Inc from 2013 to 2025. This chart illustrates how Tanvex BioPharma Inc's total liabilities have evolved over time, based on quarterly financial data.

Tanvex BioPharma Inc Competitors by Total Liabilities

The table below lists competitors of Tanvex BioPharma Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Treace Medical Concepts Inc NASDAQ:TMCI	USA	$106.91 Million
Dongsung FineTec Co. Ltd KQ:033500	Korea	₩224.84 Billion
Asia Cuanon Tech (Shanghai) SHG:603378	China	CN¥4.05 Billion
centrotherm international AG F:CTNK	Germany	€288.95 Million
Spok Holdings Inc NASDAQ:SPOK	USA	$52.93 Million
Senao International Co Ltd TW:2450	Taiwan	NT$4.54 Billion
RF Capital Group Inc TO:RCG	Canada	CA$1.06 Billion
AstroNova Inc NASDAQ:ALOT	USA	$62.23 Million

Liability Composition Analysis (2013–2025)

This chart breaks down Tanvex BioPharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 6541 total assets.

Liquidity & Leverage Metrics

Tanvex BioPharma Inc Total Liabilities Ratios Explained

Tanvex BioPharma Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	1.33	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.42	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.30	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Tanvex BioPharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Tanvex BioPharma Inc (2013–2025)

The table below shows the annual total liabilities of Tanvex BioPharma Inc from 2013 to 2025.

Year	Total Liabilities	Change
2025-12-31	NT$2.27 Billion ≈ $71.43 Million	+23.09%
2024-12-31	NT$1.84 Billion ≈ $58.03 Million	-5.17%
2023-12-31	NT$1.94 Billion ≈ $61.19 Million	-4.24%
2022-12-31	NT$2.03 Billion ≈ $63.90 Million	+5.71%
2021-12-31	NT$1.92 Billion ≈ $60.45 Million	+9.52%
2020-12-31	NT$1.75 Billion ≈ $55.20 Million	+223.18%
2019-12-31	NT$542.12 Million ≈ $17.08 Million	+105.41%
2018-12-31	NT$263.92 Million ≈ $8.31 Million	+17.93%
2017-12-31	NT$223.78 Million ≈ $7.05 Million	-25.22%
2016-12-31	NT$299.25 Million ≈ $9.43 Million	+146.47%
2015-12-31	NT$121.41 Million ≈ $3.83 Million	+86.52%
2014-12-31	NT$65.09 Million ≈ $2.05 Million	-22.16%
2013-12-31	NT$83.63 Million ≈ $2.63 Million	--

About Tanvex BioPharma Inc

TW:6541 Taiwan Biotechnology

Market Cap

$227.50 Million

NT$7.22 Billion TWD

Market Cap Rank

#15843 Global

#721 in Taiwan

Share Price

NT$27.25

Change (1 day)

-2.50%

52-Week Range

NT$27.25 - NT$63.30

All Time High

NT$287.73